title: What path do we take?
abstract: As existing biologics gain indications and new drugs make it to market, the array of choices makes it challenging to pick the right treatment for a given patient. Clinical effectiveness is the most important factor, but at the policy level, cost has to enter the discussion. Where?
authors.forename: Lola
authors.initials: L
authors.lastname: Butcher